{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Markland AD"],"funding":["NCATS NIH HHS","NCCIH NIH HHS","NIA NIH HHS","NIDDK NIH HHS","NCI NIH HHS"],"pagination":["243-252"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9742141"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["209(1)"],"pubmed_abstract":["<h4>Purpose</h4>Our goal was to evaluate vitamin D supplementation for preventing or treating overactive bladder and urinary incontinence in men.<h4>Materials and methods</h4>Ancillary study of men aged ≥55 years in VITAL (VITamin D and OmegA-3 TriaL). Randomized treatments included: vitamin D<sub>3</sub> (cholecalciferol), marine omega-3 fatty acids, or matching placebo. Structured urinary incontinence questions measured the prevalence of overactive bladder at year 5 and urinary incontinence at years 2 and 5, along with incidence and progression of urinary incontinence from years 2 to 5. Prespecified subgroup analyses examined men with low baseline serum 25-hydroxyvitamin D (<20 ng/mL).<h4>Results</h4>Among the 11,486 men who provided data at year 2 and 10,474 at year 5, mean age was 68 years at year 2, with 23% racial/ethnic minorities. In primary analyses, vitamin D supplementation compared to placebo did not lower odds of overactive bladder at year 5 (OR 0.97, 95% CI 0.87-1.08) or weekly urinary incontinence at year 2 (OR 0.94, 95% CI 0.83-1.05) or year 5 (OR 0.98, 95% CI 0.88-1.09). We found interactions of baseline serum 25-hydroxyvitamin D level with vitamin D supplementation for overactive bladder (<i>P</i> value for interaction = .001), and secondarily, for any urinary incontinence at year 2 (<i>P</i> value for interaction = .05). Men with baseline 25-hydroxyvitamin D <20 ng/mL, who were assigned to vitamin D supplements, had lower odds of overactive bladder (OR 0.51, 95% CI 0.35-0.76) compared to placebo, yet higher odds of any urinary incontinence (OR 1.24, 95% CI 0.93-1.64).<h4>Conclusions</h4>Overall, vitamin D supplementation did not improve overactive bladder or urinary incontinence compared to placebo. However, specific use of vitamin D in men with lower 25-hydroxyvitamin D levels had inconsistent findings."],"journal":["The Journal of urology"],"pubmed_title":["Effect of Vitamin D Supplementation on Overactive Bladder and Urinary Incontinence Symptoms in Older Men: Ancillary Findings From a Randomized Trial."],"pmcid":["PMC9742141"],"funding_grant_id":["R01 AT011729","U01 CA138962","R01 CA138962","UL1 TR002378","K24 AG073586","R01 DK115473","K24 AG068601"],"pubmed_authors":["Tangpricha V","Vaughan CP","Bubes VY","Manson JE","Cook NR","Lee IM","Kim E","Buring JR","Markland AD","Grodstein F","Huang AJ"],"additional_accession":[]},"is_claimable":false,"name":"Effect of Vitamin D Supplementation on Overactive Bladder and Urinary Incontinence Symptoms in Older Men: Ancillary Findings From a Randomized Trial.","description":"<h4>Purpose</h4>Our goal was to evaluate vitamin D supplementation for preventing or treating overactive bladder and urinary incontinence in men.<h4>Materials and methods</h4>Ancillary study of men aged ≥55 years in VITAL (VITamin D and OmegA-3 TriaL). Randomized treatments included: vitamin D<sub>3</sub> (cholecalciferol), marine omega-3 fatty acids, or matching placebo. Structured urinary incontinence questions measured the prevalence of overactive bladder at year 5 and urinary incontinence at years 2 and 5, along with incidence and progression of urinary incontinence from years 2 to 5. Prespecified subgroup analyses examined men with low baseline serum 25-hydroxyvitamin D (<20 ng/mL).<h4>Results</h4>Among the 11,486 men who provided data at year 2 and 10,474 at year 5, mean age was 68 years at year 2, with 23% racial/ethnic minorities. In primary analyses, vitamin D supplementation compared to placebo did not lower odds of overactive bladder at year 5 (OR 0.97, 95% CI 0.87-1.08) or weekly urinary incontinence at year 2 (OR 0.94, 95% CI 0.83-1.05) or year 5 (OR 0.98, 95% CI 0.88-1.09). We found interactions of baseline serum 25-hydroxyvitamin D level with vitamin D supplementation for overactive bladder (<i>P</i> value for interaction = .001), and secondarily, for any urinary incontinence at year 2 (<i>P</i> value for interaction = .05). Men with baseline 25-hydroxyvitamin D <20 ng/mL, who were assigned to vitamin D supplements, had lower odds of overactive bladder (OR 0.51, 95% CI 0.35-0.76) compared to placebo, yet higher odds of any urinary incontinence (OR 1.24, 95% CI 0.93-1.64).<h4>Conclusions</h4>Overall, vitamin D supplementation did not improve overactive bladder or urinary incontinence compared to placebo. However, specific use of vitamin D in men with lower 25-hydroxyvitamin D levels had inconsistent findings.","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Jan","modification":"2026-05-28T01:55:41.371Z","creation":"2025-04-04T03:00:15.721Z"},"accession":"S-EPMC9742141","cross_references":{"pubmed":["36067369"],"doi":["10.1097/JU.0000000000002942","10.1097/ju.0000000000002942"]}}